• Publications
  • Influence
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme atExpand
  • 877
  • 27
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the major regulatory enzyme of the mevalonate pathway of cholesterol synthesis), displays antitumor activity inExpand
  • 382
  • 21
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
R115777 is a nonpeptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity inExpand
  • 468
  • 14
  • PDF
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
PURPOSE To ascertain if hepatic or renal dysfunction leads to increased toxicity at a given dose of gemcitabine and to characterize the pharmacokinetics of gemcitabine and its major metabolite inExpand
  • 171
  • 7
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.
The purpose of this study was to determine the maximum tolerated dose and dose-limiting toxicities of fish oil fatty acid capsules containing omega-3 fatty acid ethyl esters. Twenty-two patients withExpand
  • 116
  • 7
  • PDF
Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.
Reproducible and characteristic clinical findings of fever, skin rash, capillary leak and pulmonary infiltrates have been observed during engraftment in patients with autologous bone marrow (BM)Expand
  • 128
  • 6
Anti-cancer therapy: targeting the mevalonate pathway.
The mevalonate pathway has become an important target for anti-cancer therapy. Manipulation of this pathway results in alteration of malignant cell growth and survival in cell culture and animalExpand
  • 129
  • 5
Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.
A sensitive, nonradioactive analytical method has been developed to simultaneously determine the concentrations of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) in culturedExpand
  • 69
  • 5
Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
A primary cellular target of the clinical nitrogenous bisphosphonates is the isoprenoid biosynthetic pathway. Specifically these drugs inhibit the enzyme farnesyl pyrophosphate synthase and depleteExpand
  • 62
  • 5
Isoprenoids: Remarkable diversity of form and function
The isoprenoid biosynthetic pathway is the source of a wide array of products. The pathway has been highly conserved throughout evolution, and isoprenoids are some of the most ancient biomoleculesExpand
  • 173
  • 4